The search for replacements for unfractionated heparin.
Antman
E M
EM
Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts, USA. eantman@rics.bwh.harvard.edu
D000208:Acute Disease; D000991:Antithrombins / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003327:Coronary Disease / Q000188:drug therapy*; D017985:Dalteparin / Q000009:adverse effects / Q000627:therapeutic use; D017984:Enoxaparin / Q000009:adverse effects / Q000627:therapeutic use; D005343:Fibrinolytic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006493:Heparin / Q000627:therapeutic use*; D006495:Heparin, Low-Molecular-Weight / Q000009:adverse effects / Q000627:therapeutic use*; D024764:Hirudin Therapy; D006801:Humans; D017762:Nadroparin / Q000009:adverse effects / Q000627:therapeutic use; D013917:Thrombin / Q000037:antagonists & inhibitors; D013995:Time
D000991:Antithrombins; D017984:Enoxaparin; D005343:Fibrinolytic Agents; D006495:Heparin, Low-Molecular-Weight; D017762:Nadroparin; D006493:Heparin; D013917:Thrombin; D017985:Dalteparin